EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Target Cell Activation of a Structurally Novel NOD-Like Receptor Pyrin Domain-Containing Protein 3 Inhibitor NT-0796 Enhances Potency

Pamela Smolak, MyTrang Nguyen, Christine Diamond, Heather Wescott, John R Doedens, Kenneth Schooley, John N Snouwaert, Mark G Bock, David Harrison, Alan P Watt, Beverly H Koller, Christopher A Gabel

The Journal of Pharmacology and Experimental Therapeutics · 2024

DOI: 10.1124/jpet.123.001941 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2024. Verfasst von Pamela Smolak und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (B.H.K., M.N., J.N.S.); Nodthera, Seattle Washington…. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, NLR Proteins. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome is a central regulator of innate immunity, essential for processing and release of interleukin-1β and pyroptotic cell death. As endogenous NLRP3 activating triggers are hallmarks of many human chronic inflammatory diseases, inhibition of NLRP3 has emerged as a therapeutic target. Here we identify NDT-19795 as a novel carboxylic acid-containing NLRP3 activation inhibitor in both human and mouse monocytes and macrophages. Remarkably, conversion of the carboxylate to an isopropyl-ester (NT-0796) greatly enhances NLRP3 inhibitory potency in human monocytes. This increase is attributed to the ester-containing pharmacophore being more cell-penetrant than the acid species and, once internalized, the ester being metabolized to NDT-19795 by carboxylesterase-1 (CES-1). Mouse macrophages do not express CES-1, and NT-0796 is ineffective in these cells. Mice also contain plasma esterase (Ces1c) activity which is absent in humans. To create a more human-like model, we generated a mouse line in which the genome was modified, removing Ces1c and replacing this segment of DNA with the human CES-1 gene driven by a mononuclear phagocyte-specific promoter. We show human CES-1 presence in monocytes/macrophages increases the ability of NT-0796 to inhibit NLRP3 activation both in vitro and in vivo. As NLRP3 is widely expressed by monocytes/macrophages, the co-existence of CES-1 in these same cells affords a unique opportunity to direct ester-containing NLRP3 inhibitors precisely to target cells of interest. Profiling NT-0796 in mice humanized with respect to CES-1 biology enables critical modeling of the pharmacokinetics and pharmacodynamics of this novel therapeutic candidate. SIGNIFICANCE STATEMENT: Inhibition of NLRP3 represents a desirable therapeutic strategy for the treatment of multiple human disorders. In this study pharmacological properties of a structurally-novel, ester-containing NLRP3 inhibitor NT-0796 are characterized. To study pharmacodynamics of NT-0796 in vivo, a mouse line was engineered possessing more human-like traits with respect to carboxylesterase biology. In the context of these hCES-1 mice, NT-0796 serves as a more effective inhibitor of NLRP3 activation than the corresponding acid, highlighting the full translational potential of the ester strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NLR Family, Pyrin Domain-Containing 3 ProteinNLR ProteinsHumansAnimalsMicePyrin DomainInflammasomesCaspase 1EstersCarboxylic Ester HydrolasesInterleukin-1beta

Substanzen

NLR Family, Pyrin Domain-Containing 3 ProteinNLR ProteinsInflammasomesCaspase 1EstersCarboxylic Ester HydrolasesInterleukin-1beta

Autor:innen und Institutionen

  • Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (B.H.K., M.N., J.N.S.); Nodthera, Seattle Washington (P.S., C.D., H.W., J.R.D., K.S., C.A.G.); Nodthera, Cambridge, United…

Zitieren

APA

Smolak, P., Nguyen, M., Diamond, C., Wescott, H., Doedens, J. R., Schooley, K., Snouwaert, J. N., Bock, M. G., Harrison, D., Watt, A. P., Koller, B. H., & Gabel, C. A. (2024). Target Cell Activation of a Structurally Novel NOD-Like Receptor Pyrin Domain-Containing Protein 3 Inhibitor NT-0796 Enhances Potency. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.123.001941

Vancouver

Smolak P, Nguyen M, Diamond C, Wescott H, Doedens JR, Schooley K, et al. Target Cell Activation of a Structurally Novel NOD-Like Receptor Pyrin Domain-Containing Protein 3 Inhibitor NT-0796 Enhances Potency. The Journal of Pharmacology and Experimental Therapeutics. 2024. doi:10.1124/jpet.123.001941

BibTeX
@article{Smolak2024,
  author = {Smolak, Pamela and Nguyen, MyTrang and Diamond, Christine and Wescott, Heather and Doedens, John R and Schooley, Kenneth and Snouwaert, John N and Bock, Mark G and Harrison, David and Watt, Alan P and Koller, Beverly H and Gabel, Christopher A},
  title = {Target Cell Activation of a Structurally Novel NOD-Like Receptor Pyrin Domain-Containing Protein 3 Inhibitor NT-0796 Enhances Potency},
  journal = {The Journal of Pharmacology and Experimental Therapeutics},
  year = {2024},
  doi = {10.1124/jpet.123.001941}
}
Kostenlos starten →